Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation

Trial Profile

Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Atorvastatin (Primary) ; Ciclosporin; Fludarabine; Mycophenolate mofetil
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Planned primary completion date changed from 1 May 2018 to 26 May 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 13 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top